Alarm hazards top the ECRI Institute’s list of technology concerns

Laura Pedulli | | Health Exec | Digital Transformation

 

Alarm hazards rank first on the ECRI Institute’s top 10 list of medical technology concerns for 2015, reports Clinical Innovation + Technology.

The full list includes the following: 

  1. Alarm hazards: Inadequate alarm configuration policies and practices
  2. Data integrity: Incorrect or missing data in EHRs and other health IT systems
  3. Mix-up of IV lines leading to misadministration of drugs and solutions
  4. Inadequate reprocessing of endoscopes and surgical instruments
  5. Ventilator disconnections not caught because of mis-set or missed alarms
  6. Patient-handling device use errors and device failures
  7. “Dose creep”: Unnoticed variations in diagnostic radiation exposures
  8. Robotic surgery: Complications due to insufficient training
  9. Cybersecurity: Insufficient protections for medical devices and systems
  10. Overwhelmed recall and safety alert management programs

Read more below:

Alarm hazards top ECRI Institute's annual technology concerns for 2015

Laura Pedulli

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.